Business
Press Release Dec 23 2025
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 23, 2025, titled "Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®. NUFYMCO®. BLA has been approved by the USFDA".
About this update from Zydus Lifesciences Limited
[{"type":"text","content":" Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 23, 2025, titled \"Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®. NUFYMCO®. BLA has been approved by the USFDA\". View Attachment","length":419,"tagName":"div"}]